Same-day antiretroviral therapy (ART) initiation in pregnancy is not associated with viral suppression or engagement in care: A cohort study

Nontokozo Langwenya, Tamsin K Phillips, Kirsty Brittain, Allison Zerbe, Elaine J Abrams, Landon Myer, Nontokozo Langwenya, Tamsin K Phillips, Kirsty Brittain, Allison Zerbe, Elaine J Abrams, Landon Myer

Abstract

Introduction: Many prevention of mother-to-child HIV transmission programmes across Africa initiate HIV-infected (HIV positive) pregnant women on lifelong antiretroviral therapy (ART) on the first day of antenatal care ("same-day" initiation). However, there are concerns that same-day initiation may limit patient preparation before starting ART and contribute to subsequent non-adherence, disengagement from care and raised viral load. We examined if same-day initiation was associated with viral suppression and engagement in care during pregnancy.

Methods: Consecutive ART-eligible pregnant women making their first antenatal care (ANC) visit at a primary care facility in Cape Town, South Africa were enrolled into a prospective cohort between March 2013 and June 2014. Before July 2013, ART eligibility was based on CD4 cell count ≤350 cells/μL ("Option A"), with a 1 to 2 week delay from the first ANC visit to ART initiation for patient preparation; thereafter all women were eligible regardless of CD4 cell count ("Option B+") and offered ART on the same day as first ANC visit. Women were followed with viral load testing conducted separately from routine ART services, and engagement in ART services was measured using routinely collected clinic, pharmacy and laboratory records through 12 months postpartum.

Results: Among 628 HIV-positive women (median age, 28 years; median gestation at ART start, 21 weeks; 55% newly diagnosed with HIV), 73% initiated ART same-day; this proportion was higher under Option B+ versus Option A (85% vs. 20%). Levels of viral suppression (viral load <50 copies/mL) at delivery (74% vs. 82%) and 12 months postpartum (74% vs. 71%) were similar under same-day versus delayed initiation respectively. Findings were consistent when viral suppression was defined at <1000 copies/mL, after adjustment for demographic/clinical measures and across subgroups of age, CD4 and timing of HIV diagnosis. Time to first viral rebound following initial suppression did not differ by timing of ART initiation nor did engagement in care through 12 months postpartum (same-day = 73%, delayed = 73%, p = 0.910).

Conclusions: These data suggest that same-day ART initiation during pregnancy is not associated with lower levels of engagement in care or viral suppression through 12 months post-delivery in this setting, providing reassurance to ART programmes implementing Option B+.

Keywords: Option B+; Prevention of Mother to Child Transmission (PMTCT); antiretroviral initiation; patient counselling; patient preparation; pregnancy; retention; viral suppression.

© 2018 The Authors. Journal of the International AIDS Society published by John Wiley & sons Ltd on behalf of the International AIDS Society.

Figures

Figure 1
Figure 1
Probability of maintaining viral suppression (VS ART initiation since first ANC visit.

References

    1. Sperling RS, Shapiro DE, Coombs RW, Todd JA, Herman SA, McSherry GD, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med. 1996;335(22):1621–9.
    1. European Collaborative Study . Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV‐infected pregnant women. Clin Infect Dis. 2007;44(12):1647–56.
    1. Townsend CL, Cortina‐Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother‐to‐child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006. J Acquir Immune Defic Syndr. 2008;22(8):973–81.
    1. Dryden‐Peterson S, Bennett K, Hughes MD, Veres A, John O, Pradhananga R, et al. An augmented SMS intervention to improve access to antenatal CD4 testing and ART initiation in HIV‐infected pregnant women: a cluster randomized trial. PLoS ONE. 2015;10(2):e0117181.
    1. Myer L, Zulliger R, Pienaar D. Diversity of patient preparation activities before initiation of antiretroviral therapy in Cape Town, South Africa. Trop Med Int Health. 2012;17(8):972–7.
    1. Hoffman R, Black V, Technau K, Van de Merwe K, Currier J, Coovadia A, et al. Effects of highly active antiretroviral therapy duration and regimen on risk for mother‐to‐child transmission of HIV in Johannesburg, South Africa. J Acquir Immune Defic Syndr. 2010;54(1):35–41.
    1. Chibwesha CJ, Giganti MJ, Putta N, Chintu N, Mulindwa J, Dorton BJ, et al. Optimal time on HAART for prevention of mother‐to‐child transmission of HIV. J Acquir Immune Defic Syndr. 2011;58(2):224–8.
    1. World Health Organisation . Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a publich health approach. Geneva Switzerland: WHO; 2013[cited 2017 Augusut 9]. Available from: .
    1. National Department of Health . The South African antiretroviral treatment guidelines. South Africa, Pretoria: NDH; 2013. [cited 2017 Augusut 9]. Available from: .
    1. Abrams EJ, Myer L, Rosenfield A, El‐Sadr WM. Prevention of mother‐to‐child transmission services as a gateway to family‐based human immunodeficiency virus care and treatment in resource‐limited settings: rationale and international experiences. Am J Obstet Gynecol. 2007;197(3 Suppl):S101–6.
    1. Zachariah R, Reid SD, Chaillet P, Massaqoui M, Schouten EJ, Harries AD. Why do we need a point‐of‐care CD4 test for low‐income countries? Trop Med Int Health. 2011;16(1):37–41.
    1. Mnyani CN, McIntyre JA, Myer L. The Reliability of Point‐of‐Care CD4 Testing in Identifying HIV‐Infected Pregnant Women Eligible for Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2012;60(3):260–4.
    1. Siedner MJ, Lakosski AJ, Kanyesigye M, Bwana MB, Haberer JE, Bangsberg DR. A combination SMS and transportation reimbursement intervention to improve HIV care following abnormal CD4 test results in rural Uganda: a prospective observational cohort study. BMC Med. 2015;13(1):160.
    1. Wynberg E, Cooke G, Shroufi A, Ried SD, Ford N. Impact of point‐of‐care CD4 testing on linkage to HIV care: a systematic review. J Acquir Immune Defic Syndr. 2014;17:e18809.
    1. van der Merwe K, Chersich MF, Technau K, Umurungi Y, Conradie F, Coovadia A. Integration of antiretroviral treatment within antenatal care in Gauteng Province, South Africa. J Acquir Immune Defic Syndr. 2006;43(5):577–81.
    1. van Lettow M, Bedell R, Mayuni I, Mateyu G, Landes M, Chan AK, et al. Towards elimination of mother‐to‐child transmission of HIV: performance of different models of care for initiating lifelong antiretroviral therapy for pregnant women in Malawi (Option B+). J Acquir Immune Defic Syndr. 2014;17:e18994.
    1. Chan AK, Kanike E, Bedell R, Mayuni I, Mnyera R, Mlotha W, et al. Same day HIV diagnosis and antiretroviral therapy initiation affects retention in Option B+ prevention of mother‐to‐child transmission services at antenatal care in Zomba District, Malawi. J Int AIDS Soc. 2016;19:e20672.
    1. Schouten EJ, Jahn A, Midiani D, Makombe SD, Mnthambala A, Chirwa Z, et al. Prevention of mother‐to‐child transmission of HIV and the health‐related Millennium Development Goals: time for a public health approach. Lancet. 2011;378(9787):282–4.
    1. Ahmed S, Kim MH, Abrams EJ. Risks and benefits of lifelong antiretroviral treatment for pregnant and breastfeeding women: a review of the evidence for the Option B+ approach. Curr Opin HIV AIDS. 2013;8(5):474–89.
    1. Shaffer N, Abrams EJ, Becquet R. Option B+ for prevention of mother‐to‐child transmission of HIV in resource‐constrained settings: great promise but some early caution. AIDS. 2014;28(4):599–601.
    1. Gebrekristos HT, Mlisana KP, Karim QA. Patients’ readiness to start highly active antiretroviral treatment for HIV. BMJ. 2005;331(7519):772–5.
    1. Clouse K, Schwartz S, Van Rie, Bassett J, Yende N, Pettifor A. “What they wanted was to give birth; nothing else”: barriers to retention in option B+ HIV care among postpartum women in South Africa. J Acquir Immune Defic Syndr. 2014:67:e12–8.
    1. Grimes RM, Grimes DE. Readiness: the state of the science (or the lack thereof). Curr HIV/AIDS Rep. 2010;7(4):245–52.
    1. Tenthani L, Haas AD, Tweya H, Jahn A, van Oosterhout JJ, Chimbwandira F, et al. Retention in care under universal antiretroviral therapy for HIV‐infected pregnant and breastfeeding women (‘Option B+’) in Malawi. AIDS. 2014;28(4):589–98.
    1. Myer L, Zulliger R, Bekker L‐G, Abrams E. Systemic delays in the initiation of antiretroviral therapy during pregnancy do not improve outcomes of HIV‐positive mothers: a cohort study. BMC Pregnancy Childbirth. 2012;12(1):94.
    1. Gill MM, Hoffman HJ, Bobrow EA, Mugwaneza P, Ndatimana D, Ndayisaba GF, et al. Detectable Viral Load in Late Pregnancy among Women in the Rwanda Option B+ PMTCT Program: Enrollment Results from the Kabeho Study. PLoS ONE. 2016;11(12):e0168671.
    1. Myer L, Phillips TK, Zerber A, Ronan A, Hsia N, Mellins CA, et al. Optimizing antiretroviral therapy (ART) for maternal and child health (MCH): rationale and design of the MCH‐ART study. J Acquir Immune Defic Syndr. 2016;72(Suppl 2):S189.
    1. The Western Cape Government Health . Prevention of Mother‐to‐ Child Transmission Clinical Guidelines 2013. Western Cape: South Africa; 2013.
    1. Myer L, Phillips TK, McIntyre JA, Hsiao NY, Petro G, Zerbe A, et al. HIV viraemia and mother‐to‐child transmission risk after antiretroviral therapy initiation in pregnancy in Cape Town, South Africa. HIV Med. 2017;18(2):80–8.
    1. Read PJ, Mandalia S, Khan P, Harrisson U, Naftalin C, Gilleece Y, et al. When should HAART be initiated in pregnancy to achieve an undetectable HIV viral load by delivery? J Acquir Immune Defic Syndr. 2012;26(9):1095–103.
    1. Denoeud‐Ndam L, Fourcade C, Ogouyemi‐Hounto A, Azon‐Kouanou A, d'Almeida M, Azondékon A, et al. Predictive factors of plasma HIV suppression during pregnancy: a prospective cohort study in Benin. PLoS ONE. 2013;8(3):e59446.
    1. Chetty T, Newell ML, Thorne C, Coutsoudis A. Viraemia before, during and after pregnancy in HIV‐infected women on antiretroviral therapy in rural KwaZulu‐Natal, South Africa, 2010–2015. Trop Med Int Health. 2018;23(1):79–91.
    1. Chimbwandira F, Mhango E, Makombe S, Midina D, Mwansambo C, Njala J, et al. Impact of an innovative approach to prevent mother‐to‐child transmission of HIV‐Malawi, July 2011‐September 2012. MMWR Morb Mortal Wkly Rep. 2013;62(8):148–51.
    1. Haas AD, Tenthani L, Msukwa MT, Tal K, Jahn A, Gadabu OJ, et al. Retention in care during the first 3 years of antiretroviral therapy for women in Malawi's option B+ programme: an observational cohort study. Lancet HIV. 2016;3(4):e175–82.
    1. Atanga PN, Ht Ndetha, Achidi EA, Merika HD, Hoelscher M, Kroidl A, et al. Retention in care and reasons for discontinuation of lifelong antiretroviral therapy in a cohort of Cameroonian pregnant and breastfeeding HIV‐positive women initiating ‘Option B+’in the South West Region. Trop Med Int Health. 2017;22(2):161–70.
    1. Siedner MJ, Lankowski A, Haberer JE, Kembabazi A, Emenyonu N, Tsai AC, et al. Rethinking the “pre” in pre‐therapy counseling: no benefit of additional visits prior to therapy on adherence or viremia in Ugandans initiating ARVs. PLoS ONE. 2012;7(6):e39894.
    1. Chung MH, Richardson BA, Tapia K, Benki‐Nugent S, Kiarie JN, Simoni JM, et al. A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. PLoS Med. 2011;8(3):e1000422.
    1. Vaz MJ, Barros SM, Palacios R, Senise JF, Lunardi L, Amed AM, et al. HIV‐infected pregnant women have greater adherence with antiretroviral drugs than non‐pregnant women. Int J STD AIDS. 2007;18(1):28–32.
    1. World Health Organization . Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva Switzerland: 2016. [cited 2017 August 09]. Available from:

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi